The online version of this article (doi:10.1186/s12879-017-2316-x) contains supplementary material, which is available to authorized users.
Levels of non-neutralising antibodies (AB) to the C5 domain of HIV Env gp120 are inversely related to progression of HIV infection. In this phase I/II clinical study we investigated safety of Vacc-C5, a peptide-based therapeutic vaccine candidate corresponding to C5/gp41732–744 as well as the effects on pre-existing AB levels to C5/gp41732–744, immune activation and T cell responses including exploratory assessments of Vacc-C5-induced T cell regulation. Our hypothesis was that exposure of the C5 peptide motif may have detrimental effects due to several of its HLA-like features and that enhancement of non-neutralising anti-C5 AB by vaccination could reduce C5 exposure and thereby chronic immune activation.
Thirty-six HIV patients on effective antiretroviral therapy were randomised to one of three dose levels of Vacc-C5 administered intramuscularly with Alhydrogel or intradermally with GM-CSF as adjuvant through initial immunisation and two booster periods over 26 weeks. Vacc-C5-specific AB were measured by ELISA and T cell responses by both IFN-γ ELISPOT and proliferative assays analysed by flow cytometry. Immune regulation was assessed by functional blockade of the two inhibitory cytokines IL-10 and TGF-β in parallel cultures. Non-parametric statistical tests were applied.
Vacc-C5 was found safe and well tolerated in all patients. Only marginal changes in humoral and cellular responses were induced, without any effect on immune activation. Overall, anti-Vacc-C5 AB levels seemed to decrease compared to pre-existing levels. Whereas Vacc-C5-specific CD8+ T cell proliferative responses increased after the first booster period (p = 0.020; CD4+, p = 0.057), they were reduced after the second. In contrast, Vacc-C5-induced T cell regulation increased after completed vaccination (p ≤ 0.027) and was lower at baseline in the few AB responders identified (p = 0.027).
The therapeutic HIV vaccine candidate Vacc-C5 safely induced only marginal immune responses, whereas Vacc-C5-induced T cell regulation markedly increased. Our data support further attention on immune regulation during therapeutic HIV vaccination studies.
Additional file 1: Supporting data. (XLSX 16 kb)12879_2017_2316_MOESM1_ESM.xlsx
2014 Global statistics. Available at http://www.unaids.org/en/resources/documents/2015/AIDS_by_the_numbers_2015, accessed 30 Nov 2015.
French MA, King MS, Tschampa JM, da Silva BA, Landay AL. Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells. J Infect Dis. 2009;200:1212–5. CrossRefPubMed
Cadogan M, Austen B, Heeney JL, Dalgleish AG. HLA homology within the C5 domain promotes peptide binding by HIV type 1 gp120. AIDS Res Hum Retroviruses. 2008; 24:845-55.
Cadogan M, Dalgleish AG. Pathogenesis of HIV: non-specific immune hyperactivity and its implications for vaccines. Clin Med. 2008;8:267–71.
Disis ML, Bernhard H, Shiota FM, et al. Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood. 1996;88:202–10. PubMed
Brekke K, Lind A, Holm-Hansen C, et al. Intranasal administration of a therapeutic HIV vaccine (Vacc-4x) induces dose-dependent systemic and mucosal immune responses in a randomized controlled trial. PLoS One. 2014; doi: 10.1371/journal.pone.0112556.
Ökvist M, Sommerfelt M, Stjernholm G, et al. Baseline antibody levels to C5/gp41 732–744: a potential prognostic marker for viral load outcome following immunization with the peptide-based therapeutic HIV vaccine, Vacc-4x (abstract WEPE094). In: Program and abstracts of the 20 th International AIDS Conference (Melbourne, Australia); 2014. Available at http://www.aids2014.org accessed at 30 Nov 2015.
Lind A, Brekke K, Pettersen FO, Mollnes TE, Troseid M, Kvale D. A parameter for IL-10 and TGF-ß mediated regulation of HIV-1 specific T cell activation provides novel information and relates to progression markers. PLoS One. 2014; doi: 10.1371/journal.pone.0085604.
- The therapeutic HIV Env C5/gp41 vaccine candidate Vacc-C5 induces specific T cell regulation in a phase I/II clinical study
Anne Margarita Dyrhol-Riise
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II